Blueprint
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending 15 March
2017
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline plc (the 'Company')
Conditional Share Awards
As
previously announced, on 15 February 2017 the Company granted
conditional awards to certain Executive Directors and Persons
Discharging Managerial Responsibilities ('PDMR'). This
announcement relates to a PDMR who elected to participate in the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan ('DABP') in respect
of his bonus on a post-tax basis. The awards have been granted in
accordance with the rules of the DABP which was approved by
shareholders on 20 May 2009.
Participants
are required to defer 25% of any bonus earned into Ordinary Shares
or ADSs and may be eligible to choose to invest up to an additional
25% (i.e. up to a maximum of 50%) pre-tax (Deferred Bonus Award)
and/or post-tax (Co-investment shares).
The
Company will match the Deferred Bonus Award or Co-investment shares
up to one-for-one depending on the achievement of performance
targets (Matching Award). Details of the performance measures will
be confirmed later in the year following shareholder approval of
the Remuneration Policy at the Company's Annual General
Meeting.
The
performance period for the awards is the three financial years from
1 January 2017 to 31 December 2019.
The
awards of deferred, co-investment and matching shares have been
granted as conditional awards over ADSs for US pre-tax participants
and as nil-cost options over Ordinary Shares for all other
participants.
The
vesting date for these conditional awards will be the later of the
date, following the end of the three year performance period, on
which the Remuneration Committee determines the extent to which the
performance measures have been achieved, the third anniversary of
the Award Date or such other later date as determined by the
Remuneration Committee.
The
amounts shown below are the maximum amounts payable (exclusive of
dividend reinvestment during the performance period). The
actual pay-out will be determined by performance over the period.
Progress against targets will be reported in the Company's Annual
Report yearly.
Transaction notification
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
|
a)
|
Name
|
Mr B McNamara
|
|
b)
|
Position/status
|
CEO, Consumer Healthcare
|
|
c)
|
Initial
notification / amendment
|
Initial Notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
|
a)
|
Description of
the financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of the
transaction
|
1)
Acquisition of post-tax Co-investment ADSs (under the
GlaxoSmithKline 2009 Deferred Annual Bonus Plan).
2)
Acquisition of a matching award conditional award of ADSs (under
the GlaxoSmithKline 2009 Deferred Annual Bonus Plan) subject to
performance measures.
|
|
c)
|
Price(s)
and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
|
|
$41.61
|
2,087
|
|
|
|
$41.61
|
2,087
|
|
|
|
|
|
|
|
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
4,174
$41.61
|
|
e)
|
Date
of the transaction
|
2017-03-14
|
|
f)
|
Place
of the transaction
|
New York Stock Exchange (XNYS)
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: March
15, 2017
|
|
|
|
|
|
|
By: VICTORIA
WHYTE
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|